BioNexus Gene Lab Corp Liquidation Value

BioNexus Gene Lab Corp (BGLC) is a Malaysia-based holding company operating three segments: industrial chemical trading (Chemrex, ~99% of revenue), genomic screening services (MRNA Scientific, de minimis), and investment holding. Period end is December 31, 2025. Total assets per XBRL are $9.25M against total liabilities of $638K, producing reported book equity of $8.61M. However, under a liquidation lens, recovery to equity is substantially lower and likely negative on a cash basis once asset haircuts are applied against face-value liabilities.

Asset-side liquidation assessment: Cash and equivalents of $2.49M recovers at par. Trade receivables gross $1.21M carry an allowance of $704K, leaving net $506K; at 90% recovery that yields ~$455K. Inventory of $677K at 60% yields ~$406K. Fixed deposits (included in current deposits of $1.66M and non-current deposits of $1.55M, total ~$3.21M) are likely term deposits at Malaysian banks and may recover near par, though the filing does not separately tag them as cash equivalents—assumed 90-95% recovery. PP&E net $1.60M (gross $2.54M, accumulated depreciation $869K, accumulated impairment $40K) consists predominantly of land and buildings at cost $1.51M and lab/machinery equipment; at a 50-60% PP&E haircut, liquidation value is roughly $800K-$960K. Right-of-use assets ($178K) recover at zero under liquidation. Investments in equity securities of $2.03M are entirely securities without readily determinable fair value (privately held companies, ASC 321 measurement alternative), carried at cost less impairment; liquidation realizable value is highly uncertain—filing does not provide observable market prices, so recovery could range from zero to cost. The largest single item ($1.78M) is the Fidelion Diagnostics stake, acquired via stock issuance in November 2025 and classified Level 3; no impairment has been taken. Under a conservative liquidation lens, these should be haircut severely (assume 0-30% recovery).

Liability side at face value: Total liabilities are $638K, comprising current liabilities of $521K (trade payables $2K, other payables $276K, accrued liabilities $126K, advance from customers $8K, current lease liability $59K, and a prepaid other asset reclassification item of $83K representing first installment due to Fidelion) and non-current liabilities of $117K (non-current lease liability). Finance debt appears minimal. The Fidelion licensing commitment of $2.0M in 24 monthly installments and a minimum $500K reagent purchase commitment are disclosed in MD&A but are NOT separately XBRL-tagged as a liability on the balance sheet as of December 31, 2025—only the first installment ($83K) appears in other payables. The remaining $1.92M+ of license obligations and $500K purchase commitment represent off-balance-sheet exposure that would not extinguish on wind-up.

Net loss for FY2025 was $2.98M vs $1.60M in FY2024, a 87% deterioration. Share-based compensation of $795K (up from $141K in 2024) was the primary driver of the investment-holding segment loss of $1.71M. Provision for expected credit losses of $271K in 2025 vs $884K in 2024 represents improvement, but the gross AR allowance stands at $704K against gross AR of $1.21M—a 58% allowance rate signaling persistent collections risk in the Chemrex segment. A significant internal control deficiency at Chemrex was flagged in the prior 10-Q (September 30, 2025) and four Chemrex officers/directors resigned in December 2025; as of filing the Company has not reached conclusions on courses of action. The Ethereum treasury strategy announced March 2025 is disclosed in significant events but no Ethereum holdings appear on the balance sheet as of December 31, 2025—filing does not separately tag any digital asset balance in XBRL, and no Ethereum is disclosed in the financial statements for this period.